Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312214 | 0.84 | SMYD2 (0.39) | SMYD2 | |
| SCHEMBL25309181 | 0.84 | SMYD2 (0.39) | SMYD2 | |
| SCHEMBL30159081 | 0.80 | TAAR1 (0.37) | SMYD2TAAR1 | |
| SCHEMBL19714856 | 0.79 | SCN9A (0.37) | SMYD2TAAR1POLB | |
| SCHEMBL18170205 | 0.78 | NT5E (0.39) | SMYD2TAAR1 | |
| SCHEMBL31129547 | 0.78 | CHRNB2 (0.52) | — | |
| SCHEMBL19730177 | 0.78 | TAAR1 (0.36) | SMYD2TAAR1POLB | |
| SCHEMBL25309312 | 0.76 | SLC18A2 (0.43) | POLBSLC18A2 | |
| SCHEMBL19714829 | 0.76 | TAAR1 (0.34) | SMYD2TAAR1POLB | |
| SCHEMBL19714910 | 0.76 | TAAR1 (0.34) | SMYD2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | SMYD2 2056/4885TAAR1 4596/4885POLB 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.